• Featured Product
  • KD/KO Validated

CHRNB4 Polyclonal antibody

CHRNB4 Polyclonal Antibody for WB, FC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, FC, ELISA

Conjugate

Unconjugated

Cat no : 22192-1-AP

Synonyms

CHRNB4



Tested Applications

Positive WB detected inSH-SY5Y cells, HeLa cells, mouse testis tissue
Positive FC detected inSH-SY5Y cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:1000-1:4000
Flow Cytometry (FC)FC : 0.20 ug per 10^6 cells in a 100 µl suspension
Sample-dependent, check data in validation data gallery

Product Information

The immunogen of 22192-1-AP is CHRNB4 Fusion Protein expressed in E. coli.

Tested Reactivity human, mouse
Cited Reactivity human
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen CHRNB4 fusion protein Ag16767 相同性解析による交差性が予測される生物種
Full Name cholinergic receptor, nicotinic, beta 4
Calculated molecular weight 498 aa, 56 kDa
Observed molecular weight 48-60 kDa
GenBank accession numberBC096080
Gene symbol CHRNB4
Gene ID (NCBI) 1143
RRIDAB_11232227
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Protocols

Product Specific Protocols
WB protocol for CHRNB4 antibody 22192-1-APDownload protocol
FC protocol for CHRNB4 antibody 22192-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanFC

Mar Drugs

Differential Expression of Nicotine Acetylcholine Receptors Associates with Human Breast Cancer and Mediates Antitumor Activity of αO-Conotoxin GeXIVA.

Authors - Zhihua Sun
humanWB

Eur J Pharmacol

Identification of nicotinic acetylcholine receptor subunits in different lung cancer cell lines and the inhibitory effect of alpha-conotoxin TxID on lung cancer cell growth.

Authors - Jiang Qian
humanWB

Cancers (Basel)

An Integrated Genomic Strategy to Identify CHRNB4 as a Diagnostic/Prognostic Biomarker for Targeted Therapy in Head and Neck Cancer.

Authors - Yi-Hsuan Chuang
  • KO Validated
humanWB

Mar Drugs

Cervical Cancer Correlates with the Differential Expression of Nicotinic Acetylcholine Receptors and Reveals Therapeutic Targets.

Authors - Yiqiao Liu